This episode focuses on the rapidly evolving treatment landscape for HER2-positive upper GI cancers, with major attention on MATTERHORN, DESTINY-Gastric04, and Horizon-GEA-01. Drs. Hornstein, Brown, and Grewal highlight how perioperative immunotherapy is changing care in localized disease, while trastuzumab deruxtecan is establishing itself in the second-line setting and zanidatamab-based combinations appear poised to move into the frontline. The group also weighs important practical issues such as toxicity management, repeat HER2 testing, and how to interpret trial designs when control arms may lag behind modern standards. Altogether, the conversation captures a moment when biomarker-driven therapy is clearly improving outcomes in gastroesophageal cancer, even as new sequencing questions emerge.
Contributors:
Dr. Nicholas Hornstein, MD, PhD, is a gastrointestinal medical oncologist and Assistant Professor Northwell Health.
Dr. Timothy Brown, MD, MSCE, is a gastrointestinal medical oncologist and Assistant Professor at UT Southwestern.
Dr. Udhayvir Grewal, MD, MBBS, is a gastrointestinal medical oncologist and Assistant Professor at Emory University School of Medicine.
